Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Authors: M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu

Source: Frontiers in Immunology, Vol 9 (2018)

Subject Terms: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fimmu.2018.01641/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/17b92398321047eeaf8c549f096a771f

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Authors: M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu

Source: Frontiers in Immunology, Vol 9 (2018)

Subject Terms: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fimmu.2018.01355/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/9bf5ab108c46412582e14a20102da357